Providing optimal care for patients with diabetic eye disease

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

The study demonstrated that the number of injections needed gradually decreased during the follow-up period